ProCE Banner Activity

CheckMate 274: Exploratory Analysis of DFS According to Select Biomarkers in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma Receiving Adjuvant Nivolumab

Slideset Download
Conference Coverage
Exploratory analyses from CheckMate 274 show that pretreatment tumor and immune features were positively correlated with DFS in patients with high-risk muscle-invasive UC receiving adjuvant nivolumab following radical resection.

Released: September 22, 2022

Expiration: September 21, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.